Immune-Related Response Criteria Stable Disease

2020 ◽  
Author(s):  
Keyword(s):  
Stable Disease ◽  
Response Criteria ◽  
Related Response

RECIST 1.1 versus immune-related RECIST and immune-related response criteria in assessing response to nivolumab in patients with lung, renal, and head and neck cancers.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e14609-e14609
Author(s):  
Surabhi Pathak ◽  
Marina Messinger ◽  
Michael Russell Mullane
Keyword(s):  
Head And Neck ◽  
Stable Disease ◽  
Evaluation Criteria ◽  
Cook County ◽  
Ease Of Use ◽  
Response Criteria ◽  
Fisher Exact Test ◽  
Response Evaluation ◽  
Recist 1.1 ◽  
Related Response

e14609 Background: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is reported to underestimate response to immunotherapeutic drugs. Therefore, immune related RECIST (iRECIST) based on RECIST 1.1 and immune related response criteria (IRRC) based on WHO response criteria have been studied, mainly in patients with melanoma. Whether RECIST 1.1 underestimates responses in other cancers is not well known. Aim of the present study is to assess response rates to PDL-1 inhibitor Nivolumab in lung, renal and head and neck (H&N) cancers using RECIST 1.1, iRECIST and IRRC. Methods: We reviewed patients from 2012 to present with lung, renal, H&N cancers treated with Nivolumab at John h Stroger Jr. Hospital of Cook County. Incomplete charts and those treated for less than 4 cycles of Nivolumab were excluded. Data was analyzed using descriptive statistics and Fisher exact test. Results: 47 charts were reviewed, 27 met the inclusion criteria. 17 lung (14 adeno, 3 squamous), 7 renal (5 clear cell) and 3 H&N cancer patients were included. Average age was 58.2yrs, 20(74%) were male. Average treatment was for 13 cycles. Response was assessed after at least 4 cycles. Disease control rate for lung, renal, head and neck cancer was 70%,58%, 33% respectively with RECIST 1.1 criteria compared to 77%, 71% and 66% respectively using immune RECIST or IRRC (P > 0.05). No patient developed pseudoprogression. Two had progressive disease per RECIST 1.1 but stable disease with iRECIST and IRRC. 26 of the 27 patients showed concordance between iRECIST and IRRC. One patient had stable disease per iRECIST but partial response per IRRC. Average survival after treatment initiation was 8.3 months for lung, 9.1 months for renal and 5.6 months for H&N cancer. Treatment was discontinued in 2 patients based on progression per RECIST 1.1, both patients had stable disease per iRECIST& IRRC. Conclusions: Trend towards underestimation of treatment response using RECIST 1.1 criteria compared to iRECIST or IRRC was observed. Strong concordance was observed between iRECIST and IRRC. Given relative ease of use, iRECIST might be favored over IRRC in response evaluation for immunotherapeutic drugs.

scholarly journals Adaptation of the Immune Related Response Criteria: Irrecist

2014 ◽  
Vol 25 ◽  
pp. iv369 ◽  
Author(s):  
O. Bohnsack ◽  
A. Hoos ◽  
K. Ludajic
Keyword(s):  
Response Criteria ◽  
Related Response

Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel

1999 ◽  
Vol 17 (2) ◽  
pp. 501-501 ◽  
Author(s):  
John A. Bridgewater ◽  
Ann E. Nelstrop ◽  
Gordon J.S. Rustin ◽  
Martin E. Gore ◽  
William P. McGuire ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Stable Disease ◽  
Progression Free Survival ◽  
Response Rates ◽  
Response Criteria ◽  
Ca 125 ◽  
Free Survival ◽  
Median Progression Free Survival ◽  
Standard Response

PURPOSE: To assess CA-125 as a measure of response in patients treated with paclitaxel. PATIENTS AND METHODS: One hundred forty-four patients treated with paclitaxel derived from four different trials and 625 patients treated with platinum from two trials were analyzed using precisely defined 50% and 75% reductions in CA-125. The standard and CA-125 response rates to paclitaxel and platinum were compared. In addition, we analyzed individual patient groups in which there was a difference in response according to the two response criteria. RESULTS: Patients with stable disease as determined by standard criteria who were treated with platinum and responded according to CA-125 criteria have an improved median progression-free survival compared with patients with stable disease who did not respond according to CA-125 criteria (10.6 v 4.8 months; P < .001). Standard and CA-125 response rates for patients treated with platinum (58.93% v 61.31%, respectively) and paclitaxel (30.65% v 31.67%, respectively) were very similar, as were rates of false-positive prediction of response by CA-125 (platinum 2.2% and paclitaxel 2.9%). Responders to paclitaxel had a significantly improved progression-free survival compared with nonresponders by both standard criteria (median progression-free survival, 6.8 v 2.5 months; P < .001) and CA-125 criteria (median progression-free survival, 6.8 v 3.4 months; P < .001). CONCLUSION: For assessing activity of therapy for ovarian cancer, these data show that precise 50% or 75% CA-125 response criteria are as sensitive as standard response criteria. We propose that they may be used as a measure of response in lieu of or in addition to standard response criteria in clinical trials involving epithelial ovarian cancer. Sensitivity is maintained whether patients are treated with platinum or paclitaxel.

CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology

2015 ◽  
Vol 21 (22) ◽  
pp. 4989-4991 ◽  
Author(s):  
Axel Hoos ◽  
Jedd D. Wolchok ◽  
Rachel W. Humphrey ◽  
F. Stephen Hodi
Keyword(s):  
Response Criteria ◽  
Clinical Activity ◽  
20Th Anniversary ◽  
Related Response

scholarly journals Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

2013 ◽  
Vol 19 (14) ◽  
pp. 3936-3943 ◽  
Author(s):  
Mizuki Nishino ◽  
Anita Giobbie-Hurder ◽  
Maria Gargano ◽  
Margaret Suda ◽  
Nikhil H. Ramaiya ◽  
...  
Keyword(s):  
Tumor Response ◽  
Response Criteria ◽  
Common Language ◽  
Related Response

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 ◽  
Vol 15 (23) ◽  
pp. 7412-7420 ◽  
Author(s):  
J. D. Wolchok ◽  
A. Hoos ◽  
S. O'Day ◽  
J. S. Weber ◽  
O. Hamid ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Immune Therapy ◽  
Response Criteria ◽  
Related Response

Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3006-3006 ◽  
Author(s):  
F. Stephen Hodi ◽  
Antoni Ribas ◽  
Adil Daud ◽  
Omid Hamid ◽  
Caroline Robert ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Advanced Melanoma ◽  
Response Criteria ◽  
Related Response
Sign in / Sign up

Export Citation Format

Share Document